Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

Author： Zelnak Amelia B. Wisinski Kari B.

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|1|17-24

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.1, 2015-01, pp. : 17-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe Bettio Daniela Torri Valter Masci Giovanna Salvini Piermario Santoro Armando

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S. Perry Caroline M.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer

By Keating Gillian M.

Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. : 353-360

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio Mottolese Marcella Fabi Alessandra

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

By Plosker Greg L. Keam Susan J.

Drugs, Vol. 66, Iss. 4, 2006-01 ,pp. : 449-475

Adis International

Access to resources Recommend Favorite